Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:BLBDNASDAQ:BLUENASDAQ:CRSPNASDAQ:NTLANASDAQ:NVDANASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$22.21+0.1%$26.65$20.84▼$35.25$2.22B1.911.28 million shs2.37 million shsBLBDBlue Bird$32.93-3.0%$35.74$30.67▼$59.40$1.06B1.58660,142 shs303,118 shsBLUEbluebird bio$4.08+7.7%$5.53$3.56▼$28.60$39.67M0.76363,888 shs2.08 million shsCRSPCRISPR Therapeutics$36.99-2.8%$43.10$36.52▼$68.39$3.17B1.771.55 million shs1.60 million shsNTLAIntellia Therapeutics$8.07-3.9%$9.98$8.03▼$28.18$835.38M1.972.19 million shs2.76 million shsNVDANVIDIA$109.67-1.6%$125.01$75.61▼$195.95$2.68T1.77314.71 million shs229.05 million shsVRTXVertex Pharmaceuticals$492.69-2.0%$476.45$377.85▼$519.88$126.52B0.411.28 million shs1.28 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%-4.68%-15.68%-12.11%-32.78%BLBDBlue Bird0.00%-1.85%-6.29%-14.82%-14.11%BLUEbluebird bio0.00%+4.62%0.00%-48.09%-84.06%CRSPCRISPR Therapeutics0.00%-10.26%-15.78%-4.29%-45.73%NTLAIntellia Therapeutics0.00%-10.33%-20.02%-29.27%-70.67%NVDANVIDIA0.00%-6.82%-12.13%-20.23%+21.38%VRTXVertex Pharmaceuticals0.00%-2.09%+2.69%+23.37%+17.87%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.2231 of 5 stars4.51.00.00.03.12.50.6BLBDBlue Bird4.8799 of 5 stars3.43.00.02.83.52.54.4BLUEbluebird bio2.9698 of 5 stars3.13.00.00.02.92.51.3CRSPCRISPR Therapeutics3.3936 of 5 stars4.22.00.00.02.73.30.6NTLAIntellia Therapeutics4.4493 of 5 stars4.31.00.04.71.82.51.3NVDANVIDIA4.8841 of 5 stars4.53.01.73.03.32.51.9VRTXVertex Pharmaceuticals3.8321 of 5 stars2.33.00.03.33.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$49.45122.67% UpsideBLBDBlue Bird 2.75Moderate Buy$58.2176.78% UpsideBLUEbluebird bio 2.25Hold$51.001,150.00% UpsideCRSPCRISPR Therapeutics 2.48Hold$73.1197.64% UpsideNTLAIntellia Therapeutics 2.63Moderate Buy$37.56365.37% UpsideNVDANVIDIA 2.98Moderate Buy$171.5156.39% UpsideVRTXVertex Pharmaceuticals 2.65Moderate Buy$506.702.84% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/20/2025NVDANVIDIADA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$135.00 ➝ $125.003/20/2025NVDANVIDIAWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/19/2025NVDANVIDIAKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$190.003/19/2025NVDANVIDIAMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$162.003/19/2025NVDANVIDIAStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$180.003/19/2025NVDANVIDIASusquehannaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingPositive ➝ Positive$180.00 ➝ $180.003/19/2025NVDANVIDIACantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.003/19/2025NVDANVIDIAKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/19/2025NVDANVIDIABank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$200.00 ➝ $200.003/19/2025NVDANVIDIABenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M34.89N/AN/A$12.04 per share1.84BLBDBlue Bird$1.34B0.79$3.61 per share9.12$4.93 per share6.68BLUEbluebird bio$53.12M0.75N/AN/A$35.59 per share0.11CRSPCRISPR Therapeutics$35M90.65N/AN/A$22.52 per share1.64NTLAIntellia Therapeutics$57.88M14.43N/AN/A$11.73 per share0.69NVDANVIDIA$130.50B20.51$0.97 per share112.93$1.72 per share63.76VRTXVertex Pharmaceuticals$11.02B11.48N/AN/A$63.90 per share7.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)BLBDBlue Bird$105.55M$3.2310.206.650.848.05%75.22%22.07%5/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$45.54N/AN/AN/A-565.74%-322.46%-53.17%5/7/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.25N/AN/AN/AN/A-49.34%-40.27%5/8/2025 (Estimated)NVDANVIDIA$29.76B$2.9443.1627.561.7655.69%114.83%76.61%5/28/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$2.20N/A28.142.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2025NVDANVIDIA$0.84$0.89+$0.05$0.89$38.16 billion$39.33 billion2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/A2/10/2025Q4 2024VRTXVertex Pharmaceuticals$3.99$3.54-$0.45$3.50$2.78 billionN/A2/5/2025Q1 2025BLBDBlue Bird$0.83$0.86+$0.03$0.86$308.31 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.05%N/AN/A N/ABLBDBlue BirdN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVDANVIDIA$0.040.04%+33.42%1.36%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/26/2025NVDANVIDIAquarterly$0.010.03%3/12/20253/12/20254/2/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69BLBDBlue Bird0.491.440.73BLUEbluebird bio0.370.510.33CRSPCRISPR TherapeuticsN/A22.0722.07NTLAIntellia TherapeuticsN/A6.736.73NVDANVIDIA0.134.103.64VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%BLBDBlue Bird93.59%BLUEbluebird bio87.43%CRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%NVDANVIDIA65.27%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%BLBDBlue Bird1.10%BLUEbluebird bio1.40%CRSPCRISPR Therapeutics4.10%NTLAIntellia Therapeutics3.20%NVDANVIDIA4.23%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics51099.79 million79.33 millionOptionableBLBDBlue Bird1,38032.11 million31.76 millionOptionableBLUEbluebird bio5209.72 million9.59 millionOptionableCRSPCRISPR Therapeutics47385.77 million82.26 millionOptionableNTLAIntellia Therapeutics600103.52 million98.59 millionOptionableNVDANVIDIA26,20024.40 billion23.45 billionOptionableVRTXVertex Pharmaceuticals6,100256.79 million256.28 millionOptionableCRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA HeadlinesRecent News About These CompaniesVertex Pharmaceuticals: Advancements in T1D Program and Strategic Focus on Innovative Therapies Justify Buy RatingMarch 30 at 11:03 PM | tipranks.comAllianz SE Invests $9.59 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 30 at 7:19 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Pictet Asset Management Holding SAMarch 30 at 5:53 AM | marketbeat.comNomura Asset Management Co. Ltd. Sells 5,095 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 30 at 5:35 AM | marketbeat.comNew Age Alpha Advisors LLC Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 30 at 5:34 AM | marketbeat.comVertex Pharmaceuticals: Strategic Advancements and Promising Market Potential Drive Buy RatingMarch 29 at 12:02 PM | tipranks.comDnB Asset Management AS Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 29 at 7:19 AM | marketbeat.comdenkapparat Operations GmbH Makes New $399,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 29 at 6:57 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by UniSuper Management Pty LtdMarch 29 at 5:38 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by WINTON GROUP LtdMarch 29 at 5:22 AM | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Acquires 32,739 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 29 at 5:14 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should KnowMarch 28 at 10:02 PM | msn.comIs Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?March 28 at 8:28 PM | insidermonkey.comVertex Pharmaceuticals (VRTX) Halts VX-264 Development, Incurs $400M ImpairmentMarch 28 at 6:43 PM | gurufocus.comNetflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'March 28 at 8:58 AM | benzinga.comNorges Bank Buys New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 28 at 7:40 AM | marketbeat.comLoomis Sayles & Co. L P Buys 704,575 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 28 at 6:47 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by NEOS Investment Management LLCMarch 28 at 6:40 AM | marketbeat.comRattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great RecessionMarch 28 at 6:30 AM | fool.comSava Infond d.o.o. Invests $656,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 28 at 6:21 AM | marketbeat.comElo Mutual Pension Insurance Co Sells 970 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 28 at 6:15 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA Stock Remains Stunningly Undervalued—Here’s WhyBy Thomas Hughes | March 11, 2025View NVIDIA Stock Remains Stunningly Undervalued—Here’s WhyNVIDIA Insiders Sell: This Is What It Means for the Market By Thomas Hughes | March 25, 2025View NVIDIA Insiders Sell: This Is What It Means for the Market 3 Stocks With Ironclad Balance Sheets for Long-Term StabilityBy Leo Miller | March 13, 2025View 3 Stocks With Ironclad Balance Sheets for Long-Term StabilityWhat GTC 2025 Signals for NVIDIA Stock’s Next Big MoveBy Thomas Hughes | March 19, 2025View What GTC 2025 Signals for NVIDIA Stock’s Next Big Move3 Magnificent 7 Stocks Trading Near 50-Day Lows—Time to Buy?By Sarah Horvath | March 13, 2025View 3 Magnificent 7 Stocks Trading Near 50-Day Lows—Time to Buy?CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Company DescriptionsBeam Therapeutics NASDAQ:BEAM$22.21 +0.02 (+0.09%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$22.20 -0.01 (-0.05%) As of 03/28/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Blue Bird NASDAQ:BLBD$32.93 -1.03 (-3.03%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$32.94 +0.01 (+0.02%) As of 03/28/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States, Canada, and internationally. The company operates through two segments, Bus and Parts. It offers Type C, Type D, and specialty buses; and alternative power options through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. The company also sells replacement bus parts; and provides financing services and extended warranties related to its products. Blue Bird Corporation sells its products through drop ship and a network of dealers, as well as directly to fleet operators, the United States government, and state governments; independent service centers; and maintains a parts distribution center. Blue Bird Corporation was founded in 1927 and is headquartered in Macon, Georgia.bluebird bio NASDAQ:BLUE$4.08 +0.29 (+7.65%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$4.45 +0.37 (+9.07%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$36.99 -1.05 (-2.76%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$36.90 -0.09 (-0.24%) As of 03/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$8.07 -0.33 (-3.93%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.06 -0.01 (-0.06%) As of 03/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.NVIDIA NASDAQ:NVDA$109.67 -1.76 (-1.58%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$109.02 -0.65 (-0.59%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.Vertex Pharmaceuticals NASDAQ:VRTX$492.69 -9.86 (-1.96%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$488.15 -4.54 (-0.92%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
